Drug intelligence / Profile preview

Slavinorm

Development stage
Unknown
Lead developer
Samson-Med
Modality
Peptides
Administration
Intramuscular
01

Overview

Slavinorm is a peptide-based bioregulator and geroprotector derived from calf aorta extract. It is primarily indicated for the treatment of obliterating atherosclerosis of the lower extremity arteries (peripheral arterial disease). The drug exerts antiatherogenic and antiischemic effects by optimizing the blood-lipid profile—specifically increasing high-density lipoproteins (HDL) and decreasing other cholesterol fractions—and improving microcirculation through the optimization of vascular endothelial function. Clinical studies have demonstrated its efficacy in increasing pain-free walking distance (PFWD) and improving the ankle-brachial index (ABI) in patients with stage IIb atherosclerosis. It is administered via intramuscular injection and has also shown potential antiischemic effects in models of acute myocardial infarction by reducing necrotic zones and post-occlusion arrhythmias.

Brand names
Slavinorm
Other names
calf aorta extractaorta peptidespeptides of the aorta of cattle

Beyond the preview

Go deeper on Slavinorm.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Slavinorm.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call